This is a 12-week study of levetiracetam added to a second generation antipsychotic in early
psychosis patients who have been ill for less than 5 years and continue to experience
psychotic symptoms despite at least 8 weeks of antipsychotic treatment. Levetiracetam
(Keppra) is a medication approved for the treatment of epilepsy; it reduces excessive
activity in the brain. This study will test the hypotheses that adding levetiracetam will
improve psychotic symptoms that are unresponsive to antipsychotic treatment and will protect
the brain from atrophy (volume loss). .